Skip to main content
SpringerLink
Log in

Chemotherapie im Alter

  • Leitthema
  • Published:
Der Urologe, Ausgabe A Aims and scope Submit manuscript

Zusammenfassung

Die Inzidenz maligner Erkrankungen steigt mit dem Alter exponentiell an. Das Alter an sich stellt keine Kontraindikation für die Durchführung einer Chemotherapie dar. Allerdings sollte durch Erfassung von Komorbidität und funktionellem Status älterer Patienten eine an die eingeschränkte Organfunktion angepasste Dosisreduktion erfolgen. Unter dieser Voraussetzung ist auf dem Boden der bisher zur Verfügung stehenden Datenlage davon auszugehen, dass die Chemotherapie bei alten Menschen die gleiche Wirksamkeit und das gleiche Nebenwirkungsspektrum zeigt wie bei jüngeren Patienten. Klinische Studien zur Überprüfung der Wirksamkeit von Chemotherapie im Alter ist eine wichtige urologische Aufgabe und befindet sich bereits in Planung.

Abstract

The incidence of cancer is age-related and increases rapidly. The age itself is not a contraindication for chemotherapy. Essential is the evaluation of comorbidity and the functional status of the elderly. Due to the physiologic decline in renal function and hepatic drug metabolism with age, the doses of chemotherapeutic agents should be adapted in the elderly. The elderly remain underrepresented in clinical trials. In the absence of comprehensive data on treatment in the elderly, it can be expected that response rates and toxicity to chemotherapy will be the same as in younger patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Alberson PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156: 127–132

    PubMed  Google Scholar 

  2. Balducci L, Parker M, Sexton W, Tantranond P (1989) Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 16: 76–84

    CAS  PubMed  Google Scholar 

  3. Balducci L, Extermann M (1997) Cancer Chemotherapy in older patients; what the medical oncologist needs to know. Cancer 80: 1317–1322

    CAS  PubMed  Google Scholar 

  4. Balducci L, Hardy CL, Lyman GH (2000) Hematopoetic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 7: 539–547

    CAS  PubMed  Google Scholar 

  5. Becker N (1998) Wie misst man das Krebsrisiko? Dtsch Ärzteblatt A 95: 2034–2037

  6. Becker N (1999) Epidemiologie von Tumoren. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York, S 173–216

  7. Berrino F, Sant M, Verdecci A, Copaccia R, Hakulinen T, Esteve J (1995) Survival of cancer patients in Europe. The EUROCARE Study, IARC Scientific Publications 132. International Agency for research on cancer, Lyon, France

  8. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifiying prognostic comorbidity in logitudinal studies: development and validation. J Chronic Dis 40: 373–383

    CAS  PubMed  Google Scholar 

  9. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993–1996. J Clin Epidemiol 52: 1131–1136

    Article  CAS  PubMed  Google Scholar 

  10. Cole P, Rodu B (1996) Declinining cancer mortality in the United States. Cancer 78: 2045–2048

    Article  CAS  PubMed  Google Scholar 

  11. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4: 419–428

    Google Scholar 

  12. De Rijke JM, Schouten LJ, Hillen HFP, Kiemeney LAL, Coebergh J-WJ, van den Brandt PA (2000) Cancer in the very elderly dutch population. Cancer 89: 1121–1133

    Article  PubMed  Google Scholar 

  13. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16: 1582–1587

    CAS  PubMed  Google Scholar 

  14. Froehner M, Koch R, Litz R et al. (2003) Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology 61: 596–600

    Article  PubMed  Google Scholar 

  15. Gail DB, Lenfant C (1992) The aging respiratory system. In: Evans JG; Williams TF (eds) Oxford textbook of geriatric medicine. University Press, Oxford, pp 337–348

  16. Greenfield S, Blanco DM, Elashoff RM, Ganz PA (1987) Patients of care related to age of breast cancer patients. JAMA 257: 2766–2770

    CAS  PubMed  Google Scholar 

  17. Harrison DE, Astle CM, Stone M (1989) Numbers and functions of transplantable primitive immunohematopoietic stem cells, Effects of age. J Immunol 142: 3833–3840

    CAS  PubMed  Google Scholar 

  18. Harvard Report on Cancer Prevention (1996) Causes of human cancer, Vol. 1. Cancer Causes Control 7 (Suppl 1): 55–58

    Google Scholar 

  19. Ibrahim NK, Hortobagyi GN, Ewer M et al. (1999) Doxyrubicin incuded congestive heart failure in elderly patients with metastatic breast cancer, with long term follow-up; the MD Anderson experience. Cancer Chemother Pharmacol 43: 471–478

    Article  CAS  PubMed  Google Scholar 

  20. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J (1998)Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 195: 914–919

    Google Scholar 

  21. Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluation the outcome of diabetes mellitus. J Chronic Dis 27: 387–404

    CAS  PubMed  Google Scholar 

  22. Karnofsky DA, Adelmann WH (1948) The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 1: 634–656

    Google Scholar 

  23. Lawton MP; Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily linving, gerontologist 9: 179–186

  24. Levi F; La Veccia C, Lucchini F, Negri E (1996) Worlwide trends in cancer mortality in the elderly, 1955–1992. Eur J Cancer 4: 652–672

    Article  Google Scholar 

  25. Lindemann RD (1990) Overview: renal physiology and pathophysiology of aging. Am J Kidney Diss 16: 275–282

    Google Scholar 

  26. Lipschiz DA (1995) Age-related declines in hematopoietic reserve capacity. Semin Oncol 22 (Suppl 1): 3–5

    CAS  Google Scholar 

  27. Mahoney FI, Barthel DW (1965) Functinal evaluation. Md Med J 14: 61–65

    CAS  Google Scholar 

  28. McLachlan M (1987) Renal function and disease in the elderly; anatomic structural and vascular changes in the aging kidney. In: Nunez JFM, Cameron M (eds). Butterworths, London, pp 3–26

  29. Niedermeyer J, Bokemeyer C, Fabel H (1999) Pulmonale Toxizität. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York Tokio, pp 1393–1402

  30. Öhl (1998) Diagnostik und Therapie von Anaemien bei geriatrischen Patienten. Onkologie 1: 30–35

    Google Scholar 

  31. Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW (1999) Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 84: 652–656

    Article  CAS  PubMed  Google Scholar 

  32. Sauer H (1999): Dosismodifikationen. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York Tokio, S 990–1002

  33. Schöber C, Bokemeyer C, Dempke W (1999) Kardiale Toxizität. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York Tokio, S 1374–1384

  34. Shan K. Lincoff AM, Young JB (1996) Anthracycline-incuded cardiotoxicity. Ann Intern Med 125: 47–58

    CAS  PubMed  Google Scholar 

  35. Slevin ML, Plant H, Lynch D,. Drinkwater J, Gregory WM (1988) Who should measure quality of life, the doctor or the Patient? Br J Cancer 57: 109–112

    CAS  PubMed  Google Scholar 

  36. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA (1997) High-dose cytarabine dose modification reduces the incidence neurotoxicity in patients with renal insufficiency, J Clin Oncol 15: 833–839

    Google Scholar 

  37. Tuxen MK, Hansen SW (1994) Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20: 191–214

    CAS  PubMed  Google Scholar 

  38. Wang CQ, Udupa KB, Xiao H, Lipschitz DA (1995) Effect of age on marrow macrophage number and function. Aging Clin Exp Res 7: 379–384

    CAS  Google Scholar 

  39. Wedding U, Höffken K (1998) Grundlagen internistisch-onkologischer Therapie bei alten Patienten mit Tumorerkrankungen. Onkologie 1: 19–29

    Google Scholar 

  40. Wei JY (1995) Cardivascular comorbidity in the older cancer patient. Semin Oncol 22: 9–10

    Google Scholar 

  41. Wickramasinghe SN (1997) Bone marrow. In: Sternberg SS (ed) Histology for pathologists, 2nd edn. Lippincott-Raven, Philadelphia, S 707–742

  42. Willett WC, Colditz GA, Mueller NE (1996) Strategien zur Krebsprävention, Spezial 5, Krebsmedizin. Spektrum der Wissenschaft, Heidelberg, S 34–40

  43. Wingo PA, Ries LAG, Rosenberg HM. Miller DS, Edwards BK (1998) Cancer incidence and mortality 1973–1995. Cancer 82: 197–207

    Article  Google Scholar 

  44. Yancik R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi WK, Edwards BK (1996) Cancer ans comorbidity in older patients; a descriptive profile. Ann Epidemiol 6: 399–412

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Universitätsklinik, Essen

    G. Lümmen & H. Rübben

  2. Urologische Klinik und Poliklinik, Universitätsklinik, Hufelandstraße 55, 45122, Essen

    G. Lümmen

Authors
  1. G. Lümmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Lümmen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lümmen, G., Rübben, H. Chemotherapie im Alter. Urologe [A] 42, 1436–1444 (2003). https://doi.org/10.1007/s00120-003-0446-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-003-0446-9

Schlüsselwörter

Keywords

Search

Navigation